Skip to content

GeneDx Holdings WGS Investment Proceeds

Investment Proceeds at other companies

Natera, Inc. logo
Natera, Inc.NTRA
$0-100%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
$0-100%
Personalis, Inc. logo
Personalis, Inc.PSNL
$24.1M-45.5%
NeoGenomics logo
NeoGenomicsNEO
$0-100%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$145.1M-15.2%
Azenta logo
AzentaAZTA
-$142.66M

Other financials

Income statement

See full
Revenue$102.3M+17.4%
Gross profit$68.2M+16.6%
Operating income-$57.5M-1,163%
Net income-$63.3M-870%
EPS (diluted)-$2.16-839%

Balance sheet

See full
Cash & equivalents$94.9M-5.7%
Total debt$96.7M+82.5%
Total equity$254.1M-1.3%
Total assets$506.3M+13.4%

Cash flow

See full
Operating cash flow-$32.4M-418%
CapEx$6.5M+5.3%
Free cash flow-$38.9M-1,059%

Valuation

See full
Market cap$1.89B-24.3%
Enterprise value$1.89B-22.8%
P/S4.3×-3.3×

Profitability

See full
Gross margin69.6%+4.3pp
Operating margin-14.9%
Net margin-17.6%
FCF margin3.8%+2.1pp

Returns & leverage

See full
Return on equity-30.4%
Debt / equity0.4×+0.2×
Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt.

The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about GeneDx Holdings's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GeneDx Holdings's investment proceeds?
GeneDx Holdings (WGS) reported investment proceeds of $875K in Q1 2026.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.